Abstract：
The evidence- and consensus-based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. Four consensus conferences were held between December 2020 and July 2021. Twenty-nine experts (including clinicians and patient representatives) from 12 European countries participated. This first part of the guideline includes general information on its scope and purpose, the health questions covered, target users and a methods section. It also provides guidance on which patients should be treated with systemic therapies, as well as recommendations and detailed information on each systemic drug. The systemic treatment options discussed in the guideline comprise conventional immunosuppressive drugs (azathioprine, ciclosporin, glucocorticosteroids, methotrexate and mycophenolate mofetil), biologics (dupilumab, lebrikizumab, nemolizumab, omalizumab and tralokinumab) and janus kinase inhibitors (abrocitinib, baricitinib and upadacitinib). Part two of the guideline will address avoidance of provocation factors, dietary interventions, immunotherapy, complementary medicine, educational interventions, occupational and psychodermatological aspects, patient perspective and considerations for paediatric, adolescent, pregnant and breastfeeding patients.
摘要：
根据EuroGuiDerm指南和共识声明开发手册制定了基于证据和共识的过敏性湿疹指南。在2020年12月至2021年7月期间举行了四次共识会议。来自12个欧洲国家的29名专家（包括临床医生和患者代表）参加了会议。该指南的第一部分包括其范围和目的的一般信息，涵盖的健康问题，目标用户和方法部分。它还提供了关于哪些患者应该接受系统治疗的指导，以及有关每种全身性药物的建议和详细信息。指南中讨论的全身治疗方案包括常规免疫抑制药物（硫唑嘌呤，环孢素,糖皮质激素,甲氨蝶呤和霉酚酸酯），生物制剂(dupilumab，lebrikizumab，奈莫珠单抗,奥马珠单抗和曲洛金单抗)和Janus激酶抑制剂(abrocitinib，巴利替尼和upadacitinib)。准则的第二部分将讨论避免挑衅因素，饮食干预，免疫疗法，补充医学,教育干预,职业和心理皮肤病学方面，患者的观点和对儿科的考虑，青春期,孕妇和哺乳期患者。
